These 2 ‘Monster Growth’ Stocks Aren’t Done Climbing, Say Analysts
TipRanksSun, September 6, 2026 at 9:00 PM GMT+3 8 min read
Ask any old-school market investor and he'll tell you that the cliché is true, and 'past performance cannot guarantee future returns.' If that were true without exception, then growth investing would not be a viable option – but we all know that investors love to buy into stocks that have shown enormous growth in recent months. The 'monster growth' stocks are popular because investing into them is successful.
The key is understanding the smart middle way, and treating stocks as individuals, with idiosyncratic features that need to be taken case by case. Past performance can be a solid indicator, even if it's not a guarantee, and when it's paired with consistent long-term gains, it's a powerful indicator indeed.
You can double check that by checking in with the Wall Street analysts, the professional stock experts who've built careers and reputations on the quality of their published analyses. And right now, some of Wall Street's pros are saying that the growth stocks are not done climbing.
Promotion
55% Off TipRanks
-
Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-
Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Boil it down, and the factors to look for are strong gains, top ratings from the Street's analysts, and a solid outlook for the future. Find a stock with all of those, and chances are, you've on to someting. We've opened up the TipRanks database to get the scoop on two stocks that match that profile. Here's a closer look at them.
Adlai Nortye, Ltd. (ANL)
The first growth stock we'll look at here is Adlai Nortye, a biopharmaceutical researcher working on a global stage. The company operates at the clinical-trial stage, and has several drug candidates undergoing investigation at various early-study levels. Adlai's drug development research focuses on the creation of novel cancer therapies, based primarily on two therapeutic areas: precision RAS pathway targeted therapies, and next-gen PD-1/L1 pathway modulating immunotherapies.
The first of these therapeutic areas includes the drug candidates AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC. Together, these new drug candidates are targeting various RAS-addicted tumors, a class of malignancies that includes a large proportion of all cancers, and is particularly well-represented in such dangerous conditions as pancreatic cancer, colorectal cancer, and certain lung cancers.
AN9025 is currently undergoing a global Phase I clinical trial, and dosed the first patient earlier this year. The trial focuses on patients with advanced or metastatic solid tumors harboring RAS mutations. The first US patient in the once-daily dosing regimen was started in February, while the first US patient in the once-weekly regimen was started in July. In the first half of next year, the company expects to release initial data from the once-daily dosing segment of the study.
The second drug candidate to look at, AN4035, is a first-in-class RAS-inhibitor antibody drug conjugate (ADC) targeting CEACAM5, and it carries a highly potent pan-RAS(ON) inhibitor payload for therapeutic action. In July, the company received regulatory approval, from the Human Research Ethics Committee (HREC), in Australia for a Phase 1 clinical trial, and expects to follow up with an IND submission in the US. Patient dosing is expected to begin this year, with clinical data available during 2H27.
We should note that ANL saw its share price jump twice this year, in February and April, after two rounds of successful private-placement equity financing. Together, the two rounds raised $290 million, and the company reported having $231.9 million in liquid assets available as of June 30, 2026. This compared favorably to the $8.1 million available at the end of last year. For the year-to-date, shares in ANL have gained a truly impressive 957%.
This biotech stock has caught the attention of JonesTrading analyst Boris Peaker, a 5-star expert in the field. Peaker sees high potential in this company's research track, with solid prospects of high revenues before the 2030s run out. He writes, "In our view, Adlai's lead assets provide the company with two differentiated shots on goal for RAS-addicted malignancies, which constitute ~20% of all cancers and is particularly enriched in certain pancreatic, colorectal and lung cancer types. The company is lagging behind key competitors Revolution Medicines and Erasca, but has differentiated assets with potential for best-in-class efficacy and combinability. Currently, we are valuing ANL's two lead assets (and not AN8025) in late-line, relapse/refractory PDAC, CRC, and NSCLC until we get further clarification on which indication/settings the company will pursue for initial regulatory approvals. However, with broad approval in these indications, we estimate WW peak revenue potential of ~$10B in 2038 with a weighted average POS/market penetration of 22%/27%."
The prospect of a known timeline for profitability is an attractive feature for biopharma stocks, and Peaker rates ANL as a Buy, with a $22 price target that implies a one-year upside potential of 46.5%. (To watch Peaker's track record, click here.)
Overall, ANL's Strong Buy consensus rating, based on 4 recent reviews, is unanimous, showing that Wall Street likes what it sees here. The stock is trading for $15.01 and its $24.67 average target price is somewhat more bullish than Peaker allows, and suggests a gain of 64% on the one-year horizon. (See ANL stock forecast.)
Q32 Bio, Inc. (QTTB)
Massachusetts-based Q32, the second stock on today's list, is another biopharmaceutical research and development company. Where Adlai, above, is looking at new cancer treatments, Q32's focus is on autoimmune and inflammatory diseases. This is a rich area for new drug R&D; autoimmune and inflammatory diseases have large patient bases, and many of them have no or few viable treatment options, or are simply resistant to treatment. Q32's lead drug candidate, dubbed bempikibart, targets alopecia areata, or AA, an autoimmune disease that causes hair loss, on the head or across the whole body. AA has a patient base of some 700,000 in the US alone, and current treatment options are considered limited.
Bempikibart is a fully human anti-IL-7Rα antibody, designed to treat alopecia areata through the re-regulation of adaptive immune functions. The drug acts through the IL-7 and TSLP pathways, which have been implicated, both genetically and biologically, in driving T cell-mediated pathological processes in a range of autoimmune diseases. Both pathways contribute to the inflammation and injury that is associated with conditions such as alopecia areata. There is a high unmet medical need for the treatment of AA, and Q32 believes that bempikibart offers a new therapeutic approach to modulating the autoimmune response.
During the second quarter of this year, Q32 released positive clinical data from the SIGNAL-AA clinical trial of bempikibart. The data covered the 36-week topline results from Part B of the trial, and additional data is expected before the end of this year. The data release was one of several positive factors for the stock recently; Q32 also, in July, successfully conducted a $200 million underwritten public offering, to raise capital for further clinical trials.
The combination of highly positive clinical trial data with strong fundraising proved supportive for the stock. Shares in QTTB are up by 622% over the past year, and the company has been getting plenty of upbeat attention on Wall Street.
Typical of that was the initiation-of-coverage note from Morgan Stanley's Judah Frommer. The analyst believes that this company has a clear path forward and writes, "We see favorable risk/reward for QTTB at current levels given: 1) Ph2a efficacy within the range demonstrated by approved JAK inhibitors; 2) a targeted biologic profile with the potential to differentiate on safety, monitoring burden and off-treatment durability; and 3) a series of catalysts over the coming 12-18 months that should further define product profile, registrational path and long-term dosing strategy; underscoring a $1Bn+ (PoS-adjusted) peak sales opportunity as the AA market expands."
The strength of Frommer's conviction here is clear from his price target. He sees a $34 goal for QTTB by this time next year, suggesting a robust 183.5% upside potential. (To watch Frommer's track record, click here.)
That bullish view is shared, and even surpassed, on Wall Street generally. The 5 recent analyst reviews here are all positive, for a unanimous Strong Buy consensus rating, and the combination of an $11.99 trading price with a $41 average target price points to a 242% gain in the next 12 months. (See QTTB stock forecast.)
Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Yorumlar (0)
Giriş yaparak yorum yazabilirsin.
İlk yorumu sen yaz.